Navigation Links
Pradaxa Lawsuits Move Forward, With Scheduling of Next Status Conference in Federal Pradaxa Litigation, Bernstein Liebhard LLP Reports

New York, New York (PRWEB) May 05, 2013

Pradaxa lawsuits continue to move forward in a federal litigation currently underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to the court’s website, the next Status Conference in the Pradaxa litigation has been scheduled for May 14th at 9:00 a.m. Court documents indicate that just over 550 claims have been filed in the litigation by alleged victims of Pradaxa bleeding. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

“We regularly receive inquiries from patients who have allegedly suffered serious instances of Pradaxa bleeding. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to individuals who suffered life-threatening episodes of internal bleeding that may be associated with use of this blood thinner.

Pradaxa Bleeding
Pradaxa was approved by the U.S. Food & Drug Administration (FDA) in October 2010 to prevent strokes in patients with atrial fibrillation. According to a recent Reuters report, Pradaxa sales rose more than 11% last year, and passed the $1 billion threshold that denotes blockbuster status in the pharmaceutical industry.* Pradaxa was touted as an improvement over decades-old warfarin, but recently reported that regulators in several countries have issued alerts regarding the drug’s potential to cause dangerous internal bleeding in some patients. **

Among other things, there exists no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa. In 2011 alone, the FDA received reports of 542 deaths and 3,781 side-effect incidents tied to Pradaxa, said. Earlier this year, the Institute for Safe Medicine Practices renewed concerns about Pradaxa bleeding, when it revealed that an analysis of hemorrhage cases reported to the FDA during the second quarter of 2012 found that Pradaxa bleeding is 5 times more likely to result in death compared to warfarin bleeding.***

Victims of serious Pradaxa side effects may be eligible to collect compensation for their medical bills, lost wages, pain and suffering and more. Additional information is available at Bernstein Liebhard LLP’s website, or by calling 1-877-779-1414 to speak with a Pradaxa lawyer today.

* (April 24, 2013)
** (December 12, 2012)
*** (January 9, 2013)

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
2. DrugRisks Adds Study Showing Pradaxa Viral Infection Risk
3. DrugRisk Adds Study Showing Pradaxa May Increase Viral Infection Risk
4. 2013 Cases Involving Pradaxa Internal Bleeding Problem Allegations Now Being Investigated by Resource4thePeople Lawyers
5. DrugRisks Adds New Pradaxa Study Alert As Lawsuits Increase
6. DrugRisk Update: New Pradaxa Study Questions FDA Safety Conclusion
7. Pradaxa Internal Bleeding Claims Are Now Being Reviewed by Resource4thePeople Attorneys
8. d’Oliveira & Associates Releases New Webpage on Pradaxa Lawsuits
9. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
10. DrugRisk Pradaxa Update: Litigation Grows As New Study Adds to Risks
11. Pradaxa Lawsuits: Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
Post Your Comments:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: